Pharma Strategizes On Drug Pricing On Day One Of J.P. Morgan
Drug pricing was a big theme at the industry’s biggest business meeting of the year, and it’s poised to remain one throughout 2017. While drug makers acknowledged issues, they mostly defended their pricing strategies.
You may also be interested in...
Scrip offers some key points to watch for as Johnson & Johnson and Novartis kick off the big pharma full-year presentations Jan. 24, with Bristol-Myers Squibb, Celgene and Biogen Idec finishing off the first week of earnings season.
Pharmaceutical manufacturers have been waiting for Trump’s ax to fall – and it finally did, on the final full day of the industry’s biggest business meeting of the year.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.